Cimzia in Inflammatory Bowel Disease and Rheumatoid Arthritis 2018 Spotlight
On March 22nd, UCB Pharma announced that the U.S. FDA approved a label update that includes pharmacokinetic data showing negligible-to-low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant. What impact might this change have for use of the brand by the US physicians managing patients with autoimmune conditions for which Cimzia is indicated? See the below highlights featuring data from our quarterly tracker of the US IBD market, RealTime Dynamix™: Inflammatory Bowel Disease US, as well as our quarterly tracker of the US RA market, RealTime Dynamix™: Rheumatoid Arthritis US.
Contact [email protected] for more information about the highlighted reports or to see if your company has access to either report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.